IP Library Granted Patent US 12,285,543
Granted Patent B2
US 12,285,543 · App. 16/463,424 · Granted Apr 29, 2025

Human cell population comprising human retinal progenitor cells without an ISL1 gene for transplantation and methods of use thereof

Inventors: Michiko Mandai (Wako, JP); Masayo Takahashi (Wako, JP); Suguru Yamasaki (Kobe, JP)
Assignees: RIKEN; Sumitomo Pharma Co., Ltd.
A61L27/3804A61K9/70A61K35/30A61K35/545A61L27/3839A61P27/02C12N5/0607C12N5/062C12N5/0621C12N5/0696C12N5/10C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,543
App. No.
16/463,424
Granted
Apr 29, 2025
Kind
B2
Abstract

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.

Claims (30)

1. A human cell population for transplant, comprising human retinal cells with a modified bipolar cell-regulating gene, wherein:

i. the human retinal cells are human retinal progenitor cells derived from human pluripotent stem cells with a modified bipolar cell-regulating gene and the human retinal progenitor cells are retina and anterior neural fold homeobox (Rax)-positive and Ceh-10 Homeodomain-containing Homolog (Chx10)-positive cells; and

ii. the modified bipolar cell-regulating gene is an ISL1 gene, and the ISL1 gene is deleted in whole or part, thereby eliminating expression of ISL1 protein,

wherein the human cell population is formed as a cell aggregate and the cell aggregate comprises a retinal tissue.

2. The human cell population for transplant according to claim 1 , wherein the ISL1 gene has

(1) the nucleotide sequence of SEQ ID NO: 1, 4, or 7; or

(2) a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO: 3, 6, or 9.

3. The human cell population for transplant according to claim 1 , wherein the eliminating expression of ISL1 protein is by deletion of a region comprising an initiation codon of the ISL1 gene.

4. The human cell population for transplant according to claim 1 , wherein the human pluripotent stem cells are human induced pluripotent stem cells or human embryonic stem cells.

5. The human cell population for transplant according to claim 1 , wherein a number of the human retinal progenitor cells with the deletion of the ISL1 gene is 10% or more of a total number of cells in the human cell population for transplant.

6. The human cell population for transplant according to claim 1 , wherein a functional integration rate of photoreceptor cells induced from the human retinal progenitor cell with the deletion of the ISL1 gene after the transplant is 10% or more.

7. A culture of a human cell population for transplant, comprising:

(1) the human cell population for transplant according to claim 1 ; and

(2) a medium to maintain viability of the human cell population for transplant.

8. A pharmaceutical composition for treating a disease based on a disorder of retinal tissue or a condition of retinal tissue damage, comprising the human cell population for transplant according to claim 1 as an active ingredient.

9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition is in a form of cell sheet.

10. A therapeutic agent for a disease based on a disorder of retinal tissue or a condition of retinal tissue damage, comprising the human cell population for transplant according to claim 1 .

11. The therapeutic agent according to claim 10 , wherein the therapeutic agent is in a form of cell sheet.

12. A method for producing the human cell population for transplant according to claim 1 , comprising the following steps (1) and (2):

(1) deleting an ISL1 gene in whole or part to eliminate expression of ISL1 protein in human pluripotent stem cells to obtain in vitro, a human cell population comprising the human pluripotent stem cells with the deletion of the ISL1 gene;

(2) inducing differentiation of the cell population comprising the human pluripotent stem cells with the deletion of the ISL1 gene obtained in step (1) into human retinal progenitor cells with the deletion of the ISL1 gene in vitro to obtain the human cell population for transplant of claim 1 .

13. The method of production according to claim 12 , wherein the human cell population for transplant is in a form of cell aggregate.

14. The method of production according to claim 12 , wherein the ISL1 gene has

(1) the nucleotide sequence of SEQ ID NO: 1, 4, or 7; or

(2) a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO: 3, 6, or 9.

15. The method of production according to claim 12 , wherein the human pluripotent stem cells are human induced pluripotent stem cells or human embryonic stem cells.

16. The method of production according to claim 12 , wherein the human retinal progenitor cells with the deletion of the ISL1 gene are Rax-positive and Chx10-positive cells.

17. The method of production according to claim 12 , wherein a number of the human retinal progenitor cells with the deletion of the ISL1 gene is 10% or more of a total number of cells in the human cell population for transplant.

18. The method of production according to claim 12 , wherein a functional integration rate of photoreceptor cells induced from the human retinal progenitor cells with the deletion of the ISL1 gene after the transplant is 10% or more.

19. A method for treating a disease based on a disorder of retinal tissue or a condition of retinal tissue damage, comprising transplanting an effective amount of the human cell population for transplant according to claim 1 into a subject in need thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2025
From: SUMITOMO PHARMA CO., LTD.
To: RACTHERA CO., LTD.
Reel/Frame 072399/0820 →
CHANGE OF NAME Recorded Jul 14, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD
Reel/Frame 060507/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2019
From: MANDAI, MICHIKO; TAKAHASHI, MASAYO; YAMASAKI, SUGURU
To: RIKEN; SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 049265/0861 →
Priority Claims (2)
JP 2016-229355 · Nov 25, 2016 · national
JP 2017-138142 · Jul 14, 2017 · national
Continuity (1)
Related Publication 20190351103A1 · Nov 21, 2019
References Cited (83)
US 7390659B2 · Jessell · 2008 [cited by examiner]
US 7745113B2 · Evans · 2010 [cited by examiner]
US 8927274B2 · Itskovitz-Eldor · 2015 [cited by examiner]
US 9200252B2 · Park · 2015 [cited by examiner]
US 9328328B2 · Gamm · 2016 [cited by examiner]
US 9359592B2 · Park · 2016 [cited by examiner]
US 9683215B2 · Melton · 2017 [cited by examiner]
US 9752119B2 · Gamm · 2017 [cited by examiner]
US 9770471B2 · Eggan · 2017 [cited by examiner]
US 10221393B2 · Melton · 2019 [cited by examiner]
US 10280400B2 · Ohlemacher · 2019 [cited by examiner]
US 10982188B2 · Lako · 2021 [cited by examiner]
US 20090281163A1 · Cepko · 2009 [cited by examiner]
US 20110023143A1 · Weinstein · 2011 [cited by examiner]
US 20110065645A1 · Zou · 2011 [cited by examiner]
US 20110081719A1 · Gamm · 2011 [cited by examiner]
US 20110223140A1 · Park · 2011 [cited by examiner]
US 20110223660A1 · Park · 2011 [cited by examiner]
US 20120082623A1 · Kottmann · 2012 [cited by examiner]
US 20120207744A1 · Mendlein · 2012 [cited by examiner]
US 20140341864A1 · Nakano et al. · 2014 [cited by applicant]
US 20160251616A1 · Nakano et al. · 2016 [cited by applicant]
US 20160251618A1 · Gamm · 2016 [cited by examiner]
US 20170002319A1 · D'Alessio · 2017 [cited by examiner]
US 20170211039A1 · Ohlemacher · 2017 [cited by examiner]
US 20170218335A1 · Lako · 2017 [cited by examiner]
US 20170313981A1 · Kuwahara et al. · 2017 [cited by applicant]
US 20190218510A1 · Rao · 2019 [cited by examiner]
US 20210115397A1 · Kume · 2021 [cited by examiner]
JP 2016229355 · 2016 [cited by examiner]
JP 2017138142 · 2017 [cited by examiner]
WO 2011055855A1 · 2011 [cited by applicant]
WO 2013077425A1 · 2013 [cited by applicant]
WO 2015025967A1 · 2015 [cited by applicant]
WO 2015077498A1 · 2015 [cited by applicant]
WO 2016063986A1 · 2016 [cited by applicant]
WO WO2016103269 · 2016 [cited by examiner]
Martin-Partido et al.,Neural Regen. Res. 2015; 10:1951-1952. doi:10.4103/1673-5374.165301. [cited by examiner]
Human ISL-1 gene ID: 3670 factsheet from the NCBI website: www.ncbi.nlm.nih.gov/gene/?term=3670 retrieved on Jul. 11, 2021. [cited by examiner]
Murine ISL-1 gene ID 16392 factsheet from the NCBI website: www.ncbi.nlm.nih.gov/gene/?term=16392 retrieved on Jul. 11, 2021. [cited by examiner]
Human ISL-2 gene ID: 64843 factsheet from the NCBI website:www.ncbi.nlm.nih.gov/gene/?term=64843 retrieved on Jul. 11, 2021. [cited by examiner]
Human BHLHE23 gene ID:128408 factsheet from the NCBI website:www.ncbi.nlm.nih.gov/gene/?term=128408 retrieved on Jul. 11, 2021. [cited by examiner]
Song et al., Cell Res. Thera, 2013; 4:94. stemcellres.com/content/4/4/94. [cited by examiner]
Bassett et al., Trends in Neurosci. 2012; 35:565-573. [cited by examiner]
Collin et al., Stem Cell 2016; 34:311-321. [cited by examiner]
Jones et al., Curr. Opin. Biotechnol. 2016; 40:133-138. [cited by examiner]
Zhao et al., J. Biol. Chem. 2014, 289; 11945-11951. [cited by examiner]
Pan et al., Development, 2008; 135; 1981-1990, doi:10.1242/dev.010751. [cited by examiner]
Burgess et al. J of Cell Bio. 1990, 111:2129-2138. [cited by examiner]
Bowie et al. Science, 1990, 247:1306-1310. [cited by examiner]
Pawson et al. 2003, Science 300:445-452. [cited by examiner]
Alaoui-Ismaili et al., Cytokine Growth Factor Rev. 2009; 20:501-507. [cited by examiner]
Guo et al., PNAS 2004; 101:9205-9210. [cited by examiner]
Murine BHLHE23 gene ID: 140489 factsheet from the NCBI website: www.ncbi.nlm.nih.gov/gene/?term=140489 retrieved on Jul. 11, 2021. [cited by examiner]
Bramblett et al., Neuron, 2004; 43:779-793. [cited by examiner]
Bejarano-Escobar et al., Exp. Eye Res. 2015, 138;22-31. dx.doi.org/10.1016/j.exer.2015.06.021. [cited by examiner]
Gonzalez-Cordero et al., Nat. Biotechnol. 2013; 31:741-749. [cited by examiner]
Singh et al. ARVO Annual Meeting Abstract Apr. 2014, IOVS, 55:3989, retrieved from the IOVS website: iovs.arvojournals.org/article.aspx?articleid=2269464. [cited by examiner]
Osakada et al., Biotechnol. Genet. Eng. Rev. 2009; 26:271-334. Doi:10.5661/bger-26-297. [cited by examiner]
Whitney et al., PNAS, 2011; 108:9697-9702. [cited by examiner]
Martin-Partido et al.,Neural Regen. Res. 2015; 10: 1951-1952. [cited by examiner]
Kamao et al., “Characterization of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Sheets Aiming for Clinical Application,” Stem Cell Reports, 2: 205-218 (2014). [cited by applicant]
European Search Report issued in counterpart European Patent Application No. 17874713.5 dated May 7, 2020. [cited by applicant]
MacLaren et al., “Retinal repair by transplantation of photoreceptor precursors,” Nature, 444: 203-207 (2006). [cited by applicant]
Eiraku et al., “Self-organizing optic-cup morphogenesis in three-dimensional culture,” Nature, 472: 51-56 (2011). [cited by applicant]
Nakano et al., “Self-Formation of Optic Cups and Storable Stratified Neural Retina from Human ESCs,” Cell Stem Cell, 10: 771-785 (2012). [cited by applicant]
Kuwahara et al., “Generation of ciliary margin-like stem cell niche from self-organizing human retinal tissue,” Nature Communications, 6: 1-15 (2015). [cited by applicant]
Elshatory et al., “Islet-1 Controls the Differentiation of Retinal Bipolar and Cholinergic Amacrine Cells,” Journal of Neuroscience, 27: 12707-12720 (2007). [cited by applicant]
Assawachananont et al., “Transplantation of Embryonic and Induced Pluripotent Stem Cell-Derived 3D Retinal Sheets Into Retinal Degenerative Mice,” Stem Cell Reports, 2: 662-674 (2014). [cited by applicant]
Bramblett et al., “The Transcription Factor Bhlhb4 is Required for Rod Bipolar Cell Maturation,” Neuron, 43: 779-793 (2004). [cited by applicant]
Iida et al., “Histone demethylase Jmjd3 is required for the development of subsets of retinal bipolar cells,” PNAS, 111: 3751-3756 (2014). [cited by applicant]
Mandai et al., “Visual cell transplantation into mouse degenerative retina,” Journal of Japanese Ophthalmological Society, 113: 198 (2009) (see partial English translation). [cited by applicant]
International Search Report issued in corresponding International Patent Application No. PCT/JP2017/042238 dated Feb. 13, 2018. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion issued in corresponding International Patent Application No. PCT/JP2017/042238 dated May 28, 2019. [cited by applicant]
Santos-Ferreira et al., “Retinal transplantation of photoreceptors results in donor-host cytoplasmic exchange,” Nature Communications, 7: 13028 (2016). [cited by applicant]
Office Action issued in counterpart European Patent Application No. 17874713.5 dated Sep. 7, 2021. [cited by applicant]
Wenbin and Xiang Ping, “Research progress of retinal stem cell related genes,” JBengbu Med Coll, 37 (11) (2012). [cited by applicant]
[cited by applicant]
Yamasaki et al., “A Genetic modification that reduces ON-bipolar cells in hESC-derived retinas enhances functional Integration after transplantation,” iScience 25: 103657, Jan. 21, 2022. [cited by applicant]
Shirai et al., “Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration,” PNAS, E81-E90 (2015). [cited by applicant]
Santos-Ferreira et al., “Daylight Vision Repair by Cell Transplantation,” Stem Cells, 33: 79-90 (2015). [cited by applicant]
Perlman et al., “The Electroretinogram: ERG”, U.S. National Library of Medicine, 1-43 (2001). [cited by applicant]
Third Party Observations in European Patent Application No. 17874713.5 dated Nov. 28, 2024. [cited by applicant]